Cardiovascular Drugs — MCQs

Cardiovascular Drugs Indian Medical PG Practice Questions and MCQs

Question 71: Which of the following PDE-5 inhibitors has no significant interaction with high-fat meal intake?

A. Sildenafil
B. Vardenafil
C. Tadalafil (Correct Answer)
D. All of the above

Explanation: ### Explanation The correct answer is **Tadalafil**. **1. Why Tadalafil is correct:** The pharmacokinetics of Phosphodiesterase-5 (PDE-5) inhibitors are significantly influenced by their chemical structure and absorption profiles [2]. **Tadalafil** has a unique structure that results in a slower onset but a much longer half-life (~17.5 hours, often called "The Weekend Pill") [1]. Crucially, its absorption from the gastrointestinal tract is **not affected by food**, including high-fat meals. This provides greater flexibility for patients as it can be taken without regard to timing of meals. **2. Why the other options are incorrect:** * **Sildenafil (A) and Vardenafil (B):** Both of these drugs are rapidly absorbed, but their absorption is significantly delayed and reduced (decreased $C_{max}$ and increased $T_{max}$) when taken with a **high-fat meal**. This leads to a delayed onset of action and potentially reduced efficacy, which is why patients are typically advised to take them on an empty stomach. * **All of the above (D):** This is incorrect because the food interaction is a distinguishing pharmacological feature between the shorter-acting agents (Sildenafil/Vardenafil) and the long-acting agent (Tadalafil). **3. High-Yield Clinical Pearls for NEET-PG:** * **Duration of Action:** Sildenafil/Vardenafil (4–5 hours) vs. Tadalafil (up to 36 hours) [1]. * **PDE Selectivity:** Tadalafil also inhibits **PDE-11** (found in skeletal muscle), which can lead to the side effect of **back pain/myalgia**. * **Visual Disturbances:** Sildenafil inhibits **PDE-6** (found in the retina), causing "blue-tinted vision" (cyanopsia). * **Absolute Contraindication:** All PDE-5 inhibitors are contraindicated with **Nitrates** (e.g., Nitroglycerin) due to the risk of severe, life-threatening hypotension (synergistic increase in cGMP) [1, 2]. * **Other Uses:** Tadalafil is also FDA-approved for **Benign Prostatic Hyperplasia (BPH)** and Pulmonary Arterial Hypertension (PAH).

Question 72: Which of the following is true about quinidine?

A. It increases effective refractory period
B. Causes paradoxical tachycardia
C. Cinchonism is seen
D. All of the above (Correct Answer)

Explanation: **Explanation:** Quinidine is a **Class IA antiarrhythmic** agent derived from the cinchona bark. It acts primarily by blocking open sodium channels (decreasing the rate of depolarization) and blocking potassium channels. * **Option A (Increases Effective Refractory Period):** By blocking potassium channels during phase 3 of the action potential, quinidine prolongs the action potential duration (APD). This directly leads to an increase in the **Effective Refractory Period (ERP)**, which is a hallmark of Class IA agents. * **Option B (Paradoxical Tachycardia):** Although quinidine is used to treat arrhythmias, it possesses significant **antimuscarinic (atropine-like) properties**. In patients with atrial flutter or fibrillation, it can enhance AV conduction and increase the ventricular rate, leading to "paradoxical tachycardia." To prevent this, it is usually co-administered with a drug that slows AV conduction (like Digoxin or Beta-blockers). * **Option C (Cinchonism):** This is a classic dose-dependent adverse effect of quinidine. Symptoms include tinnitus, hearing loss, visual disturbances, headache, and dizziness. **High-Yield Clinical Pearls for NEET-PG:** * **ECG Changes:** Quinidine causes prolongation of the **QRS complex and QT interval**. * **Torsades de Pointes:** Due to QT prolongation, it can trigger this life-threatening polymorphic ventricular tachycardia. * **Drug Interactions:** Quinidine reduces the renal clearance of **Digoxin**, leading to digoxin toxicity. * **Alpha-blocking effect:** It can cause peripheral vasodilation and hypotension. * **Hematology:** It is associated with immune-mediated thrombocytopenia.

Question 73: All of the following statements about beta blockers are true EXCEPT?

A. Nebivolol is a cardioselective beta blocker.
B. Cardioselective beta blockers are relatively safe in asthma.
C. Beta blockers are contraindicated in acute congestive heart failure.
D. Atenolol is safe in renal failure. (Correct Answer)

Explanation: ### Explanation **1. Why Option D is the Correct Answer (The False Statement):** Atenolol is a **highly hydrophilic (water-soluble)** beta-blocker. Unlike lipophilic drugs (like Propranolol) which are metabolized by the liver, Atenolol is primarily excreted **unchanged by the kidneys**. Therefore, in patients with renal failure, the drug accumulates, leading to toxicity (profound bradycardia and hypotension). It requires significant dose adjustment or avoidance in renal impairment. **2. Analysis of Other Options:** * **Option A (True):** Nebivolol is a third-generation, **highly cardioselective** $\beta_1$ blocker. It also possesses unique vasodilatory properties mediated by the release of Nitric Oxide (NO) from the endothelium. * **Option B (True):** Cardioselective beta-blockers (e.g., Metoprolol, Atenolol, Bisoprolol) preferentially block $\beta_1$ receptors. While they are "relatively" safe in mild-to-moderate asthma because they avoid $\beta_2$ blockade (which causes bronchospasm), they should still be used with extreme caution as selectivity is lost at higher doses. * **Option C (True):** In **acute** decompensated heart failure, beta-blockers are contraindicated because their negative inotropic effect can further worsen cardiac output. However, they are a cornerstone of therapy in **chronic** stable heart failure (specifically Metoprolol succinate, Bisoprolol, and Carvedilol). **3. NEET-PG High-Yield Pearls:** * **Lipophilic Beta Blockers:** Propranolol, Metoprolol. (Undergo extensive first-pass metabolism; cross the Blood-Brain Barrier). * **Hydrophilic Beta Blockers:** Atenolol, Sotalol, Nadolol. (Excreted by kidneys; longer half-lives). * **Shortest Acting:** Esmolol (metabolized by RBC esterases; $t_{1/2} \approx 9$ mins). * **Longest Acting:** Nadolol. * **Beta Blockers with ISA (Intrinsic Sympathomimetic Activity):** Pindolol, Acebutolol (preferred in patients with resting bradycardia).

Question 74: Which drug causes a decrease in the late sodium current?

A. Nicorandil
B. Ranolazine (Correct Answer)
C. Trimetazidine
D. Molsidomine

Explanation: ### Explanation **Correct Answer: B. Ranolazine** **Mechanism of Action:** Ranolazine is a metabolic modulator used in the management of chronic stable angina. Its primary mechanism is the **selective inhibition of the late inward sodium current ($I_{Na}$)** in myocardial cells [1], [2]. * **Pathophysiology:** During ischemia, the late sodium current fails to inactivate, leading to an overload of intracellular sodium. This triggers the **Sodium-Calcium Exchanger (NCX)** to work in reverse, pumping sodium out and calcium in [2]. * **Effect:** By blocking the late $I_{Na}$, Ranolazine prevents intracellular calcium overload [2]. This reduces ventricular wall tension, improves myocardial oxygen supply-demand balance, and enhances diastolic relaxation [1] without significantly affecting heart rate or blood pressure. **Analysis of Incorrect Options:** * **A. Nicorandil:** This is a dual-action drug. It acts as a **Potassium ($K_{ATP}$) channel opener** (causing arterial vasodilation) and a **Nitrate** (causing venous vasodilation). * **C. Trimetazidine:** This is a metabolic modulator that acts by inhibiting the enzyme **p-FOX (partial fatty acid oxidase)** [1]. It shifts myocardial metabolism from fatty acid oxidation to glucose oxidation, which is more oxygen-efficient. * **D. Molsidomine:** A prodrug that acts as a **Nitric Oxide (NO) donor**. It is a long-acting vasodilator similar in effect to organic nitrates but does not develop pharmacological tolerance as easily. **High-Yield Clinical Pearls for NEET-PG:** * **ECG Change:** Ranolazine can cause **QT interval prolongation** [1], [3] (due to its effect on potassium channels at higher doses), yet it paradoxically has anti-arrhythmic properties [3]. * **Metabolism:** It is metabolized by **CYP3A4**; therefore, it is contraindicated with potent inhibitors like clarithromycin or ketoconazole [1]. * **Clinical Use:** It is a "second-line" agent for chronic angina, especially in patients who remain symptomatic on beta-blockers or calcium channel blockers.

Question 75: What is the primary rationale for not using an ACE inhibitor concurrently with spironolactone?

A. Hyperkalemia (Correct Answer)
B. Hypokalemia
C. Increased incidence of cough
D. Hypomagnesemia

Explanation: **Explanation:** The primary rationale for avoiding the concurrent use of ACE inhibitors (ACEIs) and spironolactone is the significantly increased risk of **life-threatening hyperkalemia**. **Mechanism:** 1. **ACE Inhibitors:** These drugs block the conversion of Angiotensin I to Angiotensin II. Since Angiotensin II is the primary stimulus for **aldosterone** release from the adrenal cortex, ACEIs lead to a decrease in aldosterone levels. 2. **Spironolactone:** This is a potassium-sparing diuretic that acts as a direct **aldosterone antagonist** at the mineralocorticoid receptors in the distal tubule. 3. **Synergy:** Both drugs ultimately inhibit the action of aldosterone, which is responsible for sodium reabsorption and potassium excretion. When used together, potassium excretion is severely impaired, leading to its accumulation in the blood. **Analysis of Incorrect Options:** * **B. Hypokalemia:** This is the opposite effect. Both drugs are "potassium-sparing." * **C. Increased incidence of cough:** While ACEIs cause a dry cough (due to bradykinin accumulation), spironolactone does not contribute to this mechanism. * **D. Hypomagnesemia:** Spironolactone tends to be magnesium-sparing; it does not typically cause low magnesium. **Clinical Pearls for NEET-PG:** * **RALES Trial:** This landmark study showed that low-dose spironolactone can be used with ACEIs in severe heart failure (NYHA Class III/IV), but only under **strict monitoring** of serum potassium and creatinine. * **Contraindication:** This combination is generally avoided if serum potassium is **>5.0 mEq/L** or if there is significant renal impairment (Creatinine >2.5 mg/dL). * **Other Drugs:** ARBs (Angiotensin Receptor Blockers) and Aliskiren (Direct Renin Inhibitor) also carry the same hyperkalemia risk when combined with spironolactone.

Question 76: Which of the following calcium channel blocking agents is used in the treatment of hypertension?

A. Prazosin
B. Lidoflazine
C. Captopril
D. Nifedipine (Correct Answer)

Explanation: **Explanation:** **Nifedipine** is the correct answer because it belongs to the **Dihydropyridine (DHP)** class of Calcium Channel Blockers (CCBs). These drugs primarily act by blocking L-type calcium channels in the vascular smooth muscle, leading to peripheral vasodilation and a reduction in systemic vascular resistance, which effectively lowers blood pressure. **Analysis of Options:** * **Prazosin (Option A):** This is a selective **alpha-1 adrenergic blocker**. While it is used for hypertension, it is not a calcium channel blocker. It is often a drug of choice for patients with comorbid Benign Prostatic Hyperplasia (BPH). * **Lidoflazine (Option B):** This is an older, non-selective calcium channel blocker primarily used as a coronary vasodilator for angina. It is not a standard treatment for hypertension and has been largely superseded by safer agents. * **Captopril (Option C):** This is an **ACE Inhibitor**. It lowers blood pressure by preventing the conversion of Angiotensin I to Angiotensin II, not by blocking calcium channels. **High-Yield NEET-PG Pearls:** * **DHP CCBs** (Nifedipine, Amlodipine) are preferred for hypertension due to their potent vasodilator effects. * **Non-DHP CCBs** (Verapamil, Diltiazem) have more prominent effects on the heart (negative inotropy/chronotropy) and are used for arrhythmias and angina. * **Side Effects:** A common side effect of Nifedipine/Amlodipine is **ankle edema** (due to precapillary vasodilation) and reflex tachycardia. * **Clinical Note:** Short-acting Nifedipine is avoided in hypertensive emergencies due to the risk of precipitous hypotension and myocardial infarction; long-acting formulations are preferred.

Question 77: Which among the following is a venodilator?

A. Hydralazine
B. Minoxidil
C. Lisinopril
D. Nitroprusside (Correct Answer)

Explanation: ### Explanation The classification of vasodilators is a high-yield topic for NEET-PG, categorized based on their site of action: **Arteriolar**, **Venous**, or **Mixed**. **1. Why Nitroprusside is Correct:** **Sodium Nitroprusside** is a **mixed (balanced) vasodilator**, meaning it acts on both arterioles and veins. It works by releasing Nitric Oxide (NO), which activates guanylyl cyclase to increase cGMP, leading to smooth muscle relaxation. By dilating veins (venodilation), it increases venous capacitance and decreases **preload**. By dilating arterioles, it decreases peripheral vascular resistance and **afterload**. This makes it a drug of choice in hypertensive emergencies. **2. Analysis of Incorrect Options:** * **Hydralazine (Option A):** This is a **pure arteriolar vasodilator**. It acts primarily on precapillary resistance vessels. Because it does not dilate veins, it does not cause orthostatic hypotension but often triggers significant reflex tachycardia. * **Minoxidil (Option B):** This is a potent **pure arteriolar vasodilator** that acts by opening ATP-sensitive $K^+$ channels. Like hydralazine, it reduces afterload but has no effect on venous capacitance (preload). * **Lisinopril (Option C):** This is an **ACE Inhibitor**. While it causes both arterial and venous dilation indirectly (by reducing Angiotensin II and increasing Bradykinin), it is primarily classified as an antihypertensive/ACEI rather than a direct-acting venodilator in the context of this pharmacological classification. **3. High-Yield Clinical Pearls for NEET-PG:** * **Pure Arteriolar Dilators:** Hydralazine, Minoxidil, Diazoxide, and Calcium Channel Blockers (Nifedipine). * **Pure Venodilators:** Nitroglycerin (at therapeutic doses; it affects arteries only at high doses). * **Mixed Dilators:** Nitroprusside, Alpha-blockers (Prazosin), and ACE Inhibitors/ARBs. * **Nitroprusside Toxicity:** Prolonged infusion can lead to **Cyanide and Thiocyanate toxicity**. The antidote is Sodium Thiosulfate or Hydroxocobalamin. * **Drug of Choice:** Nitroprusside is used in hypertensive emergencies, but it is contraindicated in pregnancy (risk of fetal cyanide poisoning).

Question 78: Calcium channel blockers act on which type of muscle?

A. Skeletal muscle
B. Smooth muscle (Correct Answer)
C. Both skeletal and smooth muscle
D. Neither skeletal nor smooth muscle

Explanation: **Explanation:** Calcium channel blockers (CCBs) primarily target **L-type voltage-gated calcium channels**. The physiological effect of these drugs is highly tissue-specific due to the different ways muscle types handle calcium for contraction. **Why Smooth Muscle is the Correct Answer:** Vascular smooth muscle relies heavily on the influx of **extracellular calcium** through L-type channels to initiate contraction. When CCBs block these channels, they prevent the calcium-calmodulin complex formation, leading to vasodilation. This makes them effective for treating hypertension and angina. CCBs also act on the **cardiac muscle** (myocardium and nodal tissue), but among the options provided, smooth muscle is the primary site of action for the dihydropyridine class (e.g., Amlodipine). **Why Other Options are Incorrect:** * **Skeletal Muscle:** Unlike smooth or cardiac muscle, skeletal muscle contraction is triggered by **intracellular calcium** released from the sarcoplasmic reticulum (via the RyR1 receptor) through a process called mechanical coupling. It does not depend on extracellular calcium influx through L-type channels; therefore, CCBs have no clinical effect on skeletal muscle strength or function. * **Both/Neither:** Since skeletal muscle is unaffected, these options are physiologically incorrect. **NEET-PG High-Yield Pearls:** * **Dihydropyridines (e.g., Nifedipine):** Act mainly on vascular smooth muscle (potent vasodilators). * **Non-Dihydropyridines (e.g., Verapamil, Diltiazem):** Act on both smooth muscle and cardiac muscle (negative inotropes and chronotropes). * **Drug of Choice:** CCBs are the preferred antihypertensives in elderly patients and those of African descent. * **Side Effect:** Peripheral edema is a common side effect of dihydropyridines due to selective precapillary vasodilation.

Question 79: Verapamil is associated with which of the following adverse effects?

A. Constipation
B. Headache
C. Bradycardia
D. Hyperglycemia (Correct Answer)

Explanation: **Explanation:** The correct answer is **D. Hyperglycemia**. **Mechanism of Action:** Verapamil is a non-dihydropyridine Calcium Channel Blocker (CCB). While its primary action is on the L-type calcium channels in the myocardium and vascular smooth muscle, it also affects the **beta cells of the pancreas**. Insulin release from these cells is a calcium-dependent process. By blocking calcium entry into pancreatic beta cells, Verapamil inhibits the exocytosis of insulin, leading to reduced insulin secretion and subsequent **hyperglycemia**. **Analysis of Incorrect Options:** * **A. Constipation:** This is the **most common** side effect of Verapamil. It occurs due to the blockade of calcium channels in the gastrointestinal smooth muscle, leading to decreased motility. (Note: While common, the question specifically targets the metabolic side effect in this context). * **B. Headache:** This is a common side effect of dihydropyridines (like Amlodipine) due to potent peripheral vasodilation, but it is less characteristic of Verapamil. * **C. Bradycardia:** Verapamil has significant negative chronotropic and inotropic effects. While it *does* cause bradycardia, in the context of this specific MCQ, hyperglycemia is the metabolic adverse effect being tested. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Verapamil is the drug of choice for **Prophylaxis of Paroxysmal Supraventricular Tachycardia (PSVT)** and Cluster Headaches. * **Contraindication:** Never co-administer Verapamil with **Beta-blockers** as it can lead to additive depression of the SA/AV node, resulting in severe bradycardia or heart block. * **Gingival Hyperplasia:** Like Phenytoin and Cyclosporine, CCBs (especially Nifedipine and Verapamil) can cause gum enlargement.

Question 80: Which of the following is a limiting adverse effect of ACE inhibitors?

A. Acidosis
B. Hypernatremia
C. Hypokalemia
D. Hyperkalemia (Correct Answer)

Explanation: ### Explanation **Correct Answer: D. Hyperkalemia** **Mechanism of Action:** ACE inhibitors (e.g., Enalapril, Lisinopril) block the conversion of Angiotensin I to Angiotensin II. A decrease in Angiotensin II leads to a subsequent reduction in **Aldosterone** secretion from the adrenal cortex. Since aldosterone is responsible for sodium reabsorption and potassium excretion in the distal nephron, its inhibition results in **potassium retention**. This can lead to clinically significant hyperkalemia, especially in patients with chronic kidney disease (CKD) or those taking potassium-sparing diuretics. **Analysis of Incorrect Options:** * **A. Acidosis:** While severe hyperkalemia can sometimes be associated with metabolic acidosis (Type 4 RTA), it is not a direct or primary limiting adverse effect of ACE inhibitors. * **B. Hypernatremia:** ACE inhibitors actually promote **natriuresis** (sodium excretion) by reducing aldosterone levels. Therefore, they are more likely to cause hyponatremia than hypernatremia. * **C. Hypokalemia:** This is the opposite of the expected effect. Hypokalemia is typically seen with diuretics like thiazides or loop diuretics, not ACE inhibitors. **High-Yield Clinical Pearls for NEET-PG:** * **The "Cough" Factor:** The most common side effect of ACE inhibitors is a **dry, hacking cough** (due to increased levels of Bradykinin and Substance P). * **Teratogenicity:** ACE inhibitors are strictly **contraindicated in pregnancy** as they cause fetal renal dysgenesis (Category X). * **Bilateral Renal Artery Stenosis:** ACE inhibitors can precipitate acute renal failure in these patients because they dilate the efferent arteriole, crashing the GFR. * **First-Dose Phenomenon:** Sudden hypotension can occur after the first dose, particularly in patients on diuretics.

Practice by Chapter

Antihypertensive Agents

Practice Questions

Drugs for Heart Failure

Practice Questions

Antiarrhythmic Drugs

Practice Questions

Antianginal Agents

Practice Questions

Lipid-Lowering Drugs

Practice Questions

Anticoagulants and Antiplatelet Drugs

Practice Questions

Thrombolytic Agents

Practice Questions

Drugs Used in Pulmonary Hypertension

Practice Questions

Drugs Used in Shock

Practice Questions

Cardiovascular Effects of Non-Cardiovascular Drugs

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free